A group of New Jersey parents has revived a federal lawsuit challenging the state’s long-standing practice of collecting, storing, and using blood samples from every newborn baby without obtaining informed parental consent. The amended complaint, filed by the public interest law firm the Institute for Justice (IJ), argues that the policy violates fundamental constitutional rights, including the Fourth Amendment’s protection against unreasonable searches and seizures and the Fourteenth Amendment’s guarantee of parental autonomy.
The case centers on New Jersey’s mandatory newborn screening program, which involves a heel-prick blood test to screen for dozens of rare diseases. While the initial screening is not in dispute, the lawsuit targets the state’s subsequent retention of the residual “blood spots” for years, a practice that came to light after it was revealed law enforcement had accessed the genetic database for a criminal investigation without a warrant.
Case Background: From Public Health to Police Investigations
Like all U.S. states, New Jersey mandates that hospitals collect blood samples from newborns to test for serious genetic and metabolic disorders. However, an investigation in 2022 by the Office of the Public Defender and the New Jersey Monitor revealed that the state’s Department of Health was storing these samples for up to 23 years and had provided them to state police to help identify a child’s father in a criminal case—all without the family’s knowledge.
This revelation prompted the initial lawsuit in November 2023, which argued that the indefinite storage and undisclosed use of infants’ genetic material constituted an unconstitutional seizure. In response to the legal pressure, the state reformed its policy in June 2024, shortening the retention period to two years for most samples. However, the plaintiffs and their attorneys at the IJ argue that this change is insufficient because it still fails to address the core issue: the lack of explicit, opt-in parental consent for any storage or use beyond the initial disease screening.
The case highlights the growing tension between public health initiatives and individual privacy rights, a central theme in the ongoing debate over biometric data privacy laws.
The Amended Complaint: A New Argument for a New Era
The lawsuit was revived after a federal judge dismissed the original case in August, ruling that the plaintiffs lacked a “possessory interest” in the blood spots because, once separated from the body, they no longer constituted property in a traditional constitutional sense.
The newly filed amended complaint directly confronts this reasoning. “People’s property and privacy interests in their blood and associated genetic material do not dissipate when that blood is taken physically from inside their bodies by state action,” the filing argues. This legal pivot attempts to establish that genetic material is fundamentally different from other physical property, as it is an inseparable and persistent component of an individual’s identity.
Crucially, the plaintiffs are now also leveraging the rapid advancement of technology as a central pillar of their argument. The complaint warns that the rise of powerful, AI-driven genomic tools dramatically magnifies the privacy risks associated with the state’s database. These tools, they argue, could make it easier to infer a vast range of sensitive information from the samples, from ancestry to medical predispositions, far beyond the scope of the original screening.
“As a mother, it concerns me that I have no way of knowing what the government is doing with my child’s genetic information after the initial testing period,” said Erica Jedynak, one of the plaintiffs. “It makes me uncomfortable knowing this information could be used by private third parties, law enforcement, or any other government agency.”
Broader Implications: The Battle for Biometric Consent
The New Jersey case forces a direct confrontation with a profound legal and philosophical question for the digital age: do we retain ownership of our unique biometric data, particularly our genetic code, after a sample has been taken? The court’s ultimate decision could set a powerful precedent. If it accepts the argument that genetic material is a persistent form of personal property, it could fundamentally reshape the legal landscape for all government biometric databases and strengthen the legal basis for an individual’s right to control their most sensitive personal data.
Furthermore, the plaintiffs’ strategic use of the potential future harm from AI represents a novel legal tactic. By focusing not just on what the state has done, but on what it could do with the data in an era of advanced AI, they are forcing the legal system to be proactive about privacy. This approach could serve as a blueprint for future litigation, where the plausible capabilities of emerging technologies are used to argue for stricter data protection and consent requirements today, rather than waiting for harm to occur. The case now returns to the U.S. District Court for the District of New Jersey for consideration.
Sources: Institute for Justice, NJ.gov, Law360
–
By Cass Kennedy
